文献速递前列腺增生与排尿功能障碍

Aquablation治疗大体积前列腺(80-150 mL)良性前列腺增生:WATER II试验6个月结果

Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial.
PubMed 文献 · BJU Int · 2019-03-29

WATER II是一项在加拿大和美国16个中心开展的多中心前瞻性研究,纳入101例前列腺体积80-150 mL的良性前列腺增生(BPH)下尿路症状(LUTS)患者,评估Aquablation的6个月安全性和有效性。主要安全性终点(3个月时Clavien-Dindo 2级及以上或任何导致持续残疾的1级事件)发生率为45.5%,达到研究设计目标<65%(P<0.001)。国际前列腺症状评分(IPSS)从基线23.2±6.3改善至3个月时6.7±5.1,达到主要疗效终点目标(P<0.001)。

要点

  • 3个月主要安全性终点事件发生率为45.5%,达到研究设计目标<65%(P<0.001)。
  • IPSS从基线23.2±6.3改善至3个月时6.7±5.1,达到主要疗效终点目标(P<0.001)。
  • 最大尿流率从8.7增至18.8 mL/s(P<0.001),排尿后残余尿量从基线131降至6个月时47(P<0.0001)。

核心结论

  • Aquablation治疗大体积前列腺(80-150 mL)BPH患者安全有效,手术或切除时间无显著增加。

研究设计与样本

  • 多中心前瞻性研究,2017年9月至12月在加拿大和美国16个中心纳入101例前列腺体积80-150 mL的BPH/LUTS男性患者。

主要发现

  • 平均前列腺体积为107 mL。
  • 术后平均住院时间为1.6天(范围:当天至6天)。
  • 3个月主要安全性终点事件发生于45.5%的患者,达到研究设计目标<65%(P<0.001)。
  • 6个月时,22%的患者发生Clavien-Dindo 2级不良事件,14%发生3级,5%发生4级。
  • 出院前8例、出院后6例记录到需要干预和/或输血的出血并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present 6-month safety and effectiveness data from a multicentre prospective study of aquablation in men with lower urinary tract symptoms (LUTS) attributable to benign prostatic hyperplasia (BPH) with prostate volumes between 80 and 150 mL. METHODS: Between September and December 2017, 101 men with LUTSattributable to BPHwere prospectively enrolled at 16 centres in Canada and the USA. RESULTS: The mean prostate volume was 107 mL. The mean length of hospital stay after the aquablation procedure was 1.6 days (range: same day to 6 days). The primary safety endpoint (Clavien-Dindo grade 2 or higher or any grade 1 event resulting in persistent disability) at 3 months occurred in 45.5% of men, which met the study design goal of < 65% (P < 0.001). At 6 months, 22% of the patients had experienced a Clavien-Dindo grade 2, 14% a grade 3 and 5% a grade 4 adverse event. Bleeding complications requiring intervention and/or transfusion were recorded in eight patients prior to discharge and in six patients after discharge. The mean International Prostate Symptom Score improved from 23.2 ± 6.3 at baseline to 6.7 ± 5.1 at 3 months, meeting the study's primary efficacy endpoint goal (P < 0.001). The maximum urinary flow rate increased from 8.7 to 18.8 mL/s (P < 0.001) and post-void residual urine volume decreased from 131 at baseline to 47 at 6 months (P < 0.0001). At 6 months, prostate-specific antigen concentration reduced from 7.1 ± 5.9 ng/mL at baseline to 4.0 ± 3.9 ng/mL, a 44% reduction. CONCLUSIONS: Aquablation is safe and effective in treating men with larger prostates (80-150 mL), without significant increase in procedure or resection time.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Desai M, Bidair M, Zorn KC, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. BJU Int. 2019. PMID: 30734990. doi:10.1111/bju.14703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。